New nerve block cocktail may slash morphine use after knee tumor surgery

NCT ID NCT07382297

Recruiting now Symptom relief Sponsor: National Cancer Institute, Egypt Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding an IPACK nerve block to a standard adductor canal block can better control pain after surgery to remove tumors around the knee. 70 adults will be randomly assigned to receive either the combined nerve blocks or standard pain medication. The main goal is to see how long it takes before patients need extra pain relief, and how much morphine they use in the first 24 hours.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bupivacaine (nerve block)
What this could lead to: If it works, this could give doctors a better way to control pain after knee tumor surgery, reducing the need for strong painkillers like morphine.
What could go wrong: This is a small, early-stage trial with only 70 people, so results may not apply to everyone. Nerve blocks carry small risks like infection or nerve damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cancer Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER PAIN

Contacts and locations

Locations

National cancer institute
RECRUITING

Cairo, 11769, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.